Abstract
Polyethylene glycol (PEG) moieties can be attached to proteins to improve their pharmacological properties. Variables such as the molecular weight and conformation of PEG chains have a bearing on the conjugate's properties and should be considered when developing pegylated proteins with desired characteristics. Recombinant interferon (IFN) alfa has been used, with limited success, to treat patients infected with hepatitis C virus. The recommended thrice-weekly administration of IFN alfa does not maintain sustained plasma concentrations of the drug, thereby adversely affecting the potential virological response. Pegylation alters the pharmacokinetic properties of IFN alfa and allows for once-weekly administration. Pegylated IFNs contain either linear PEG chains of small molecular weight, as is pegylated IFN alfa-2b (12 kD), or larger branched moieties, as in pegylated IFN alfa-2a (40 kD). There are pharmacokinetic and pharmacodynamic differences between the two IFNs. The much-increased sustained virological response rates observed with pegylated IFN alfa-2a (40 kD) and pegylated IFN alfa-2b (12 kD) support the rationale for pegylation of IFN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
